[1] |
LI Ning, ZHANG Hui, ZHOU Junhui.
Effect of sub-anesthetic dose of esketamine on chronic post-surgery pain in patients undergoing radical mastectomy of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 671-679.
|
[2] |
DU Caiying, QUAN Xianghua, SUN Caihong, YUAN Haidan.
Research progress of dalpiciclib in treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 715-720.
|
[3] |
WU Guilan, LIU Jia, SUN Hong.
Construction of a column-line graph for predicting the probability of survival in early-stage elderly HER2-positive breast cancer based on the SEER database
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(3): 283-295.
|
[4] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[5] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[6] |
FU Xiaoyu, KONG Deguang, LI Juanjuan.
Treatment progress of triple positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
|
[7] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[8] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[9] |
CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing.
Clinical application and research progress of antibody drugs conjugation in breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
|
[10] |
LI Mengxi, ZHANG Kejing, XIA Fan.
Research progress in vaccine for breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
|
[11] |
WANG Xin, WU Guodong, AN Ming, LI Gang, LIU Yang.
Advances in venlafaxine-related PK-PD relationship and influencing factors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 788-795.
|
[12] |
QIAN Jin, WANG Fengyan.
Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
|
[13] |
WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun.
Clinical research progress of palbociclib in treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
|
[14] |
CHEN Hongxiao, LIU Su, JIN Le, ZHANG Huihui, ZHANG Lei, CHEN Zhaolin.
Mechanism of Pingxiao capsule promoting breast cancer apoptosis through AKT1/β-catenin signal based on network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(12): 1321-1330.
|
[15] |
WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying.
3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
|